Clinical Overview
Desipramine is a tricyclic antidepressant indicated for the treatment of depression. It is considered one of the more tolerable tricyclics due to its relatively selective norepinephrine reuptake inhibition and reduced anticholinergic effects compared to other TCAs, making it a preferred choice when tricyclic therapy is indicated.
Primary Clinical Applications
Desipramine is indicated for the treatment of depression and has extensive off-label use for ADHD in children and adults, chronic pain conditions, and bulimia nervosa. Its activating properties make it particularly suitable for patients with depression characterized by fatigue and psychomotor retardation.
Mechanism and Clinical Profile
Desipramine is a secondary amine tricyclic that primarily blocks norepinephrine reuptake with minimal effects on serotonin. This selectivity results in fewer anticholinergic side effects compared to tertiary amine tricyclics, while maintaining antidepressant efficacy.
Clinical Advantages
Among tricyclics, desipramine has a more favorable side effect profile with less sedation, fewer anticholinergic effects, and less weight gain. It is often better tolerated in elderly patients and those who cannot tolerate the side effects of other tricyclics. Therapeutic drug monitoring is available to optimize dosing.
Prescribing Information
Dosing & Administration
Depression – Adults:
- Initial: 100-200 mg daily (may start lower and titrate)
- Range: 100-300 mg daily
- Maximum: 300 mg daily
- Maintenance: Usually 100-200 mg daily
Elderly and Adolescents:
- Initial: 25-100 mg daily
- Titrate gradually based on response and tolerance
- Maximum (elderly): 150 mg daily
Administration:
- May give as single bedtime dose or divide
- Take with food to reduce GI upset
- Consistent timing each day
Indications
- Treatment of depression
- Off-label: ADHD, chronic pain, bulimia nervosa
Contraindications
- Hypersensitivity to tricyclic antidepressants
- Use within 14 days of MAOI therapy
- Acute recovery period following myocardial infarction
- Concurrent use with linezolid or IV methylene blue
Warnings & Precautions
- Boxed Warning: Increased risk of suicidal thoughts and behavior in patients under 25 years
- Cardiovascular effects: Monitor ECG in patients with cardiac disease
- Seizure risk: May lower seizure threshold
- Anticholinergic effects: Less than other TCAs but still present
- Orthostatic hypotension: Monitor blood pressure
- Withdrawal: Taper gradually to avoid discontinuation syndrome
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CYP2D6 inhibitors: Significantly increase desipramine levels
- Type 1C antiarrhythmics: Additive cardiac effects
- CNS depressants: Enhanced sedation
- Sympathomimetics: Enhanced cardiovascular effects
Adverse Reactions
Common:
- Dry mouth, constipation, dizziness, drowsiness
- Blurred vision, urinary retention, orthostatic hypotension
Advantages over other TCAs:
- Less sedation and anticholinergic effects
- Better tolerated in elderly
- Less weight gain
Serious:
- Cardiac arrhythmias, seizures, severe hypotension
Special Populations
- Elderly: Start with lower doses, monitor for orthostatic hypotension
- CYP2D6 poor metabolizers: Require significantly lower doses
- Cardiac Disease: Requires ECG monitoring and caution
- Pregnancy: Category C – use only if benefits outweigh risks
- Therapeutic monitoring: Target levels 150-300 ng/mL
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
